This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Inari Medical (NARI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Integra LifeSciences (IART) Q2 Earnings Expected to Decline
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Integra (IART) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Integra (IART) stock based on the movements in the options market lately.
Integra's (IART) New Site to Produce Recalled Tissue Products
by Zacks Equity Research
Integra (IART) is set to recommence the manufacturing of PriMatrix and SurgiMend at its new facility in Braintree, MA.
Why Is Integra (IART) Up 26% Since Last Earnings Report?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is The Options Market Predicting A Spike In Integra LifeScience (IART) Stock?
by Zacks Equity Research
Investors need to pay close attention to Integra LifeScience (IART) stock based on the movements in the options market lately.
Deciphering Integra (IART) International Revenue Trends
by Zacks Equity Research
Examine the evolution of Integra's (IART) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Integra's (IART) Q1 Earnings Match Estimates, Margins Down
by Zacks Equity Research
Strong demand for Integra's (IART) diverse portfolio of leading brands and continued successful market adoption of CereLink contributes to its revenues.
Integra (IART) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Integra (IART) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Integra LifeSciences (IART) Q1 Earnings Expected to Decline
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Investors Should Retain Integra (IART) Stock Now
by Zacks Equity Research
Integra's (IART) strong focus on portfolio optimization and international expansion bolsters investors' confidence in the stock.
Why Is Integra (IART) Down 4% Since Last Earnings Report?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Integra LifeSciences (IART) Introduces MicroMatrix Flex
by Zacks Equity Research
Integra LifeSciences' (IART) MicroMatrix Flex has a flexible tip that delivers a flowable version of the Urinary Bladder Matrix (UBM) technology.
Integra's (IART) Q4 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Integra's (IART) Q4 revenues are impacted by the decline in the Tissue Technologies segment.
Compared to Estimates, Integra (IART) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Integra (IART) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Integra LifeSciences (IART) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of -1.11% and 0.44%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Integra (IART) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Integra (IART), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Earnings Preview: Integra LifeSciences (IART) Q4 Earnings Expected to Decline
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) Q4 Earnings Match Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0% and 2.27%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Thermo Fisher Scientific (TMO) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 0.53% and 1.40%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Investors Should Retain Integra (IART) Stock Now
by Zacks Equity Research
Investors remain optimistic about Integra (IART) due to the positive outlook for its CSS segment.
Integra (IART) to Advance ENT Division With New Buyout Deal
by Zacks Equity Research
Integra (IART) will be among the top suppliers of ENT products and technologies following the Acclarent acquisition.
Integra Gains From New Product Launches, Mounting Costs Ail
by Zacks Equity Research
Integra expands the international reach of the CUSA platform and registers DuraGen, DuraSeal, Mayfield and Duo LED lighting in the EMEA and Latin America.
Why Is Glaukos (GKOS) Down 0.4% Since Last Earnings Report?
by Zacks Equity Research
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.